Program Director: E. David Crawford, MD

The Westin Riverfront at Beaver Creek • Avon, COJanuary 24-27, 2019

29th INTERNATIONALPROSTATE CANCER UPDATE

E. David Crawford, MD is an internationally renowned urologist, distinguished endowed Professor of Surgery, Urology, and Radia-tion Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado.

Dr. Crawford is an expert in benign prostate hypertrophy, uro-logic cancers, and in particular, prostate cancer. He has authored many scientific articles, as well as textbook and book chapters. He is an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, and the Journal of Clinical Oncology.

Dr. Crawford is a member of many organizations, including the American Society of Clinical Oncology (ASCO), the Ameri-can Urological Association (AUA), and the American Association for the Advancement of Science (AAAS). He is the Founder and Chairman of the Prostate Conditions Education Council, which is responsible for raising awareness and screening of millions of men for prostate health issues. He has received many awards, in-cluding the CaP Cure Annual Award for Scientific Presentation, and has twice been presented with a “Freddie Award” for best medical documentaries. He has long been recognized as one of the Best Doctors of America, and is recognized as one of the top 20 urologists in the country for men, by Men’s Health Magazine.

Program DirectorE. David Crawford, MDProfessor of Surgery, Urology and Radiation Oncology E. David Crawford Endowed Chair in Urologic Oncology University of Colorado, Denver Aurora, CO, USA

FACULTY

David M. Albala, MD graduated with a geology degree from La-fayette College in Easton, Pennsylvania. He completed his medi-cal school training at Michigan State University and completed his surgical residency at the Dartmouth-Hitchcock Medical Cen-ter. Following this, Dr. Albala was an endourology fellow at Wash-ington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago rose from Instructor to full Professor in Urology and Ra-diology in eight years. After 10 years, he became a tenured Pro-fessor at Duke University Medical Center in North Carolina, where he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Sur-gery. He has over 180 publications in peer-reviewed journals and has authored three textbooks in endourology and two in general

urology. He is the Editor-in-Chief of the Journal of Robotic Sur-gery. Currently, Dr. Albala is Chief of Urology at Crouse Hospital in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests include robotic urological surgery, minimally invasive treatment of benign prostatic hypertrophy (BPH), and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States and overseas in countries such as India, Germany, Brazil, Australia, and Singapore. He has given operative demonstrations in over 32 countries and 23 states. Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.

David Albala, MDChief of UrologyCrouse HospitalSyracuse, NY, USA

Gerald L. Andriole, Jr., MD is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospi-tal, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri.

Dr. Andriole received his medical degree from Jefferson Medi-cal College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and com-pleted urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publi-cations and serves on the editorial boards of several prestigious

journals. He is Chairman of the Prostate Committee of the Na-tional Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and PI of the NIDDK Multidisci-plinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial as well as PI of the NIDDK Medical Ther-apy of Prostatic Symptoms (MTOPS) BPH trial, and of the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Asso-ciation, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association, the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons, among other societies.

Gerald L. Andriole, Jr., MDChief of Urologic SurgeryWashington University St. Louis, MO, USA

Jelle Barentsz, MD, PhD is the Professor of Radiology at the Ni-jmegen Medical Center, Radboud University and an internation-ally recognized researcher known for developing, validating, and implementing new MRI-techniques in oncology. He is also the Chair of the Prostate MR-Reference Center

Founding Member and Past-President of the International Cancer Imaging Society and Past-President of the European So-ciety of Urogenital Radiology (ESUR). In 1980, he earned his MD from Utrecht University and his PhD in medical research in 1990 on MRI of the urinary bladder from Radboud University Nijme-gen. Since then, he has contributed to almost 300 peer reviewed

peer-reviewed publications. One of his notable contributions involves initiating PI-RADS and, along with ESUR and Ameri-can College of Radiology, making the system a world standard, thereby enabled early selective detection of aggressive prostate cancer. Also, he enabled the rebirth of Combidex-MRI, which can detect 1.5 mm lymph node metastases of any cancer.

His Royal Decoration is the “Knight in the Order of the Dutch Lion.” In addition, he has been awarded the Wertheim Salomon-son Medal, SAR Lifetime Achievement Award, Queen Wilhelmina Research Award from the Dutch Cancer Society, and the SCBTMR Lauterbur Award.

Jelle Barentsz, MD, PhDProfessor of RadiologyNijmegen Medical Center, Radboud UniversityNijmegen, Netherlands

Sigrid Carlsson, MD, PhD, MPH is an Assistant Attending Epidemi-ologist at MSK with 13 years of prostate cancer research experi-ence and over 85 publications. Her PhD thesis stemmed from the world’s largest study of prostate cancer screening, the European Randomized Study of Screening for Prostate Cancer (ERSPC), which investigated how quality of life was affected by screening and treatment. Before pursuing postdoctoral studies in urologic oncology at MSK, Dr. Carlsson was a physician in Sweden. She obtained an MPH degree from Harvard T.H. Chan School of Pub-lic Health.

Currently, Dr. Carlsson’s research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and

follow-up of prostate cancer patients. She is also the PI of a study funded by the Patty Brisben Foundation to improve the method of asking questions about women’s sexual health. She is a co-investigator on a multi-center study funded by Movember (PI: Andrew J. Vickers, PhD) that evaluates the impact of survivorship care plans and navigation tools on patients with prostate cancer after radiotherapy. She is a co-investigator on two NIH-funded research projects, one of which investigates biomarkers and risk stratification in localized prostate cancer (PI: Hans Lilja, MD, PhD). The second project is focused on developing models to improve prostate cancer outcomes across diverse populations (PI: Ruth Etzioni, PhD).

Sigrid V. Carlsson, MD, PhD, MPHAssistant Attending EpidemiologistMemorial Sloan Kettering Cancer CenterNew York, NY, USA

Raoul S. Concepcion, MD, is the current Director of The Com-prehensive Prostate Center in Nashville, TN, and also has an ap-pointment as Clinical Associate Professor of Urology, Vanderbilt University School of Medicine. He served as a resident in general surgery and urology at Vanderbilt from 1984-1990.

Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President

of LUGPA. Along with two other urologists, founded CUSP, a uro-logic research consortium in the United States. Additionally, he serves as the Chief Urologic Clinical Officer for Integra Connect (West Palm Beach, FL), is an advisor or speaker for many com-panies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and is the current editor for Urologists in Cancer Care.

Raoul S. Concepcion, MDMedical Director, The Comprehensive Prostate CenterThe Comprehensive Prostate CenterNashville, TN, USA

Michael S. Cookson, MD, MMHC is Professor and Chairman of the De-partment of Urology at the University of Oklahoma Health Sciences Center, and holds the Donald D. Albers Endowed Chair in Urology. H has authored 240 peer-reviewed journal publications, 33 chapters of various textbooks, and is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urol-ogy residency at the University of Texas, San Antonio and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chair-man of Urologic Surgery and Director of the Urologic Oncology Fel-lowship Program at Vanderbilt University. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on Clinical Guidelines, Edu-cation and Evidenced Based Medicine. He was a member of the AUA/

ABU examination committee for 10 years, including a member of Task for Cancer, Oncology Consultant and Pathology editor. He also serves on the ABU Oral Examination Committee. He is a co-founder of the OKAT, an SUO mandated oncology examination, for which he served as Chair for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He re-ceived the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as chair of the Castration-Resistant Prostate Cancer Guideline at the AUA 2018 Annual Meeting.

Dr. Cookson recently served as the Chair of the AUA Guide-lines Committee on Castration Resistant Prostate Cancer, and has previously served as the member of the AUA Guidelines on local-ized prostate cancer. Dr. Cookson is the SUO president Elect of the Society of Urologic Oncology for the 2018-2019 term.

Michael S. Cookson, MD, MMHCProfessor and Chairman of the Department of Urology University of OklahomaOklahoma City, OK, USA

John W. Davis, MD received his B.S in Biology at Davidson Col-lege in North Carolina in 1990. He received his Medical Degree at the University of Virginia in 1994 and served his residency train-ing at Eastern Virginia Graduate School of Medicine, Norfolk, VA. Dr. Davis has had fellowship training in prostate cancer research with the Department of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, and received an American Foundation of Urologic Disease Scholar award for proteomic ap-plications in prostate cancer biomarkers. He completed a clinical fellowship in Urologic Oncology at the University of Texas, M.D. Anderson Cancer Center, in Houston Texas, and a fellowship in laparoscopic urology at Charité Hospital, Berlin, Germany, under the mentorship of Ingolf Tuerk.

Dr. Davis is an Associate Professor of Urology at the University

of Texas M.D. Anderson Cancer Center, Houston Texas, where he holds Director titles of the Urosurgical Prostate Cancer Program and Urologic Oncology clinics. His clinical interests are in patients with urologic cancers, laparoscopic/robotic surgery, and general urology. Academic interests include quality of life after prostate cancer treatment, outcomes for robotic radical prostatectomy, high risk prostate cancer trials, active surveillance for prostate cancer, and development of robotic surgical techniques for inva-sive bladder cancer. He has participated as an investigator in sev-eral Southwest Oncology Group and industry sponsored clinical trials.

Dr. Davis is board certified by the American Board of Urol-ogy and is a member professional organizations including the Society of Urologic Oncology, Endourology Society, Society of

John W Davis, MD Associate Professor of Urology MD Anderson Cancer CenterHouston, TX, USA

Robotic Surgeons, Société Internationale d’Urologie, American Urological Association, and a Fellow of the American College of Surgeons. His leadership positions in professional societies have included President of the Young Urologic Oncologists (2003-2005), and President of the Society of Urologic Robotic Surgeons (2010-2012). For the American Urological Association, he sits on the Bylaws, History, and Minimally Invasive Surgery Committees,

teaches a post-graduate course on robotic prostatectomy tech-nique, and is a member of the 2014 Leadership Training Class. He is the Treasurer for the South Central Section of the AUA, and recently appointed Online Content Editor for the AUA. His peer reviewed publication involvement is highlighted by the role of Associate Editor for Urologic Oncology for the British Journal of Urology International.

Steven E. Finkelstein, MD, FACRO currently serves as the Can-cer Center Director at BRCC at AUI in Panama City, Florida, the Co-Chair for the NRG Immunotherapy Committee, Chair of the SWOG Radiation STG Committee, on the Board of Chancellors and as the Chair of Development Committee for ACRO, Co-Chair for the 2018-2019 ACRO Scientific Program Committee, Editor-in-Chief of Contemporary Radiation Oncology, and Editor of ASCO Publications. He had been National Director of TRC, the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Ari-zona. Dr. Finkelstein is responsible for expanding patient access to advanced cancer care. Inspired by his grandmother, a cancer patient, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what sur-

gery could not. Dr. Finkelstein received his medical degree from the University of Michigan Medical School. He served a residency in General Surgery at Washington University in Saint Louis, Mis-souri, and was Chief Resident in Radiation Oncology at the Mof-fitt Cancer Center in Tampa, Florida. Dr. Finkelstein also served fellowships in Biologic Immunotherapy Clinical Cancer and Sur-gical Oncology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, American Medical Association, American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.

Steven E. Finkelstein, MD, FACROCancer Center DirectorBay Regional Cancer CenterPanama City, FL, USA

Evan R. Goldfischer, MD, MBA received his BA from Tufts Uni-versity and his MD from Cornell University Medical College. He completed his internship in general surgery and his residency in Urology at the University of Chicago. He then completed a fel-lowship in Endourology under the direction of Arthur Smith at Long Island Jewish Medical Center. Dr. Goldfischer received his MBA from the University of Massachusetts and is a Certified Phy-sician Executive. In He served as the co-founding CEO of Premier Medical Group of the Hudson Valley, as well as Founding Director of Research. He is the Chairman for Premier Care’s Foundation,

which aims to support and educate individuals who are unable to address significant issues like prostate and colon cancer. He has authored more than 100 peer reviewed abstracts and publi-cations and has lectured on six continents. Dr. Goldfischer is the Chairman of the Advanced Prostate Cancer Expert Panel for the Public Education Council of the Urology Care Foundation, which is the official foundation of the AUA. He was elected to the LUGPA Board of Directors in 2014, and was elected Secretary of LUGPA in November 2018.

Evan R. Goldfischer, MD, MBAUrologistPremier Medical GroupPoughkeepsie, NY, USA

Leonard Gomella, MD is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at the Sidney Kimmel Medical College. He joined the Jefferson fac-ulty in 1988 and was appointed Chair in 2002. He serves as Senior Director for Clinical Affairs for the NCI designated Sidney Kimmel Cancer Center at Jefferson, Clinical Director of the SKCC Network and Urology Chair for NRG (RTOG). Dr. Gomella is involved in translational basic science and clinical research in the develop-ment of new diagnostic techniques and treatments for prostate and bladder cancer through the Sidney Kimmel Cancer Center as Co-Leader of the Biology of Prostate Cancer Program. In 1992 he led the team to first use molecular techniques to detect circulat-ing tumor cells in prostate cancer He has given over 500 presen-tations, written over 400 papers, and edited dozens chapters and

monographs in the field of Urology. Dr. Gomella has authored and edited 63 editions of 17 different books for medical students, residents, and practicing physicians including the “Clinician’s Pocket Reference” (aka “The Scut Monkey Book”), “Five Minute Urology Consult” and is Editor-In-Chief of the Canadian Journal of Urology. “Recovering from Prostate Cancer”, written in 1993 by Dr. Gomella was the first book published for the general public specifically on the topic of prostate cancer.

“Best Doctors in America”, “Top Doctors for Cancer”, Philadel-phia Magazine’s “Top Doctors” have recognized him for many years for urologic oncology and prostate cancer including a 2015 national recognition in Newsweek. In 2007, Men’s Health Magazine listed Dr. Gomella as one of the 20 top urologists in the US. Awards have included the American Cancer Society “Volun-

Leonard G. Gomella, MDProfessor of UrologyThomas Jefferson University HospitalsPhiladelphia, PA, USA

teer Achievement Award” and an “NCI Achievement Award”. He has been President of the Mid-Atlantic Section of the AUA and elected to the American Association of Genitourinary Surgeons and the prestigious Clinical Society of Genitourinary Surgeons. The University of Kentucky College of Medicine awarded him an

“Distinguished Alumnus Award” in 2009. From 2015-2017 was President of the Society of Urologic Oncology. In 2015 he re-ceived a “Distinguished Contribution Award” from the AUA and Jefferson honored him with the “Jefferson Achievement Award in Medicine”.

Jason M. Hafron, MD is a partner and the Director of Research at the Michigan Institute of Urology, P.C. He is also an Associate Professor of Urology at the William Beaumont School of Medi-cine, Oakland University and the Director of Robotic Surgery at Beaumont Hospital Royal Oak. Dr. Hafron is experienced in all areas of adult urology, but specializes in the minimally invasive treatment of cancers involving the prostate, kidney and bladder utilizing laparoscopic and robotic surgery. Dr. Hafron received his Bachelor of Science degree from the University of Michigan and his Doctor of Medicine degree from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Sur-gery and Urology Residency at Albert Einstein College of Medi-

cine, Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, Ohio.

Dr. Hafron has published numerous peer reviewed articles and has presented his work at national and international meet-ings. He is the principal investigator for multiple clinical re-search trials at the Michigan Institute of Urology. He is on the Board of Directors of the United Physicians Organization, and has been certified in the specialty of Urology by the American Board of Urology.

Jason M. Hafron, MDDirector of ResearchWilliam Beaumont HospitalTroy, MI, USA

Richard Harris, MD is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA Cum Laude from Washington University in St. Louis. He then completed a year of graduate work in Biological Science at the University of Illinois in Chicago, followed by medi-cal school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in the clinical drug development and research of over 70 drug trials and has also been on the advisory

board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is the LUGPA’s President. He is a founding member, CEO and President of UroPartners, LLC, the largest group of urologists in the Midwest.

Dr. Harris is an assistant clinical professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction and kidney stone disease. Dr. Harris is one of very few Urologists skilled in Cryotherapy for prostate cancer.

Richard Harris, MDPresidentUroPartnersChicago, IL, USA

R. Jonathan Henderson, MD obtained a Bachelor of Science De-gree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his in-ternship and residency in Urology at LSUMC Hospital. During this time, he authored a number of papers and presentations.

Dr. Henderson spent the next six years in practice in Alabama where he specialized in treating disorders of the female bladder and laparoscopy. During this time, he served as a representative of Alabama to the Southeastern Section of the American Urology

Association. He also served as an assistant clinical professor of Urology at the University of Alabama.

Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association, Shreve-port Medical Society, Louisiana State Medical Society, the Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is currently serving as Secretary.

R. Jonathan Henderson, MD Regional Urology, LLC Shreveport, LA, USA

A. Karim Kader, MD, PhD is a board-certified urologist who spe-cializes in screening, detecting, treating and preventing pros-tate cancer.

As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine.

His current research interests include genetic markers of risk and outcomes in urologic cancer. In addition, he examines the impact of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader com-pleted a fellowship in urologic oncology at the University of Texas

MD Anderson Cancer Center in Houston and a residency in urol-ogy at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia.

Dr. Kader is nationally recognized for his expertise in per-forming robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for ge-netic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate can-cer treatment. He is the principal investigator in numerous clini-cal research projects and has published extensively.

A. Karim Kader, MD, PhDChief of UrologyUC San DiegoSan Diego, CA, USA

Deepak A. Kapoor, MD Chairman and CEO of Integrated Medical Professionals, PLLC (IMP) and Clinical Professor of Urology at the Icahn School of Medicine at Mount Sinai, comes to his position with extensive experience in basic science research and onco-logic surgery. Under his leadership, IMP has grown to the largest practice of its kind in the US, and is regarded as a national leader in quality management, utilization review, compliance processes and the development of coordinated clinical pathways.

Dr. Kapoor is President of Advanced Urology Centers of New York, Chairman of Health Policy and Past President of LUGPA, Chairman of SCRUBS RRG, a Director and Chairman of the Finance

Committee of Allied Urological Services, Founder and Past-Pres-ident of the Integrated Medical Foundation, and has served as a Director of UroPAC.

Dr. Kapoor is a Fellow of the American College of Physician Executives and has published and lectured extensively on clini-cal and business medical issues. He is the 2014 recipient of the Russell W. Lavengood Distinguished Service Award, as well as the 2011 Ambrose-Reed Socioeconomic Essay Award. In addition to his administrative responsibilities, Dr. Kapoor continues an ac-tive clinical practice and is consistently ranked as a Top Doctor in New York.

Deepak A. Kapoor MDChairman and CEOIntegrated Medical ProfessionalsFarmingdale, NY, USA

Lawrence I. Karsh, MD is a co-founder of The Urology Center of Colorado, where he serves as an attending urologist and Direc-tor of Research & Co-Chairman of Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator for over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He serves on the bladder cancer subcommittee and

is on the advisory board for the SUO Clinical Trials Consortium and a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank.

Dr. Karsh completed his General Surgery training at The University of Colorado Health Sciences Center (UCHSC) and his Urology residency at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meet-ings throughout the country.

Lawrence I. Karsh, MD Co-founderThe Urology Center of ColoradoDenver, CO, USA

Ronald P. Kaufman Jr., MD is a Professor of Surgery in the Divi-sion of Urology at Albany Medical College in Albany, New York. He went to Trinity College, and then medical school at George Washington University. Following his Urology residency at Duke University under the direction of David Paulson, he then joined the faculty at Albany Medical College, where he is now Profes-sor of Urology. Additionally, he was the Interim Chair of Urology when the division was in a period of transition. As a result of his extensive oncology training and interest, Dr. Kaufman developed a practice concentrating in general Urologic Oncology and cur-rently focuses primarily on renal oncology, both open and robotic.

Dr. Kaufman was a member of the inaugural AUA Leadership Program in 2004. He then went on to chair the AUA Coding and Reimbursement Committee for eight years and continues to act as a consultant to the committee. Currently, he is the AUA Advi-sor to the AMA Current Procedural Terminology (CPT) Editorial Panel and an active member of the Public Policy Council and the AUA State Advocacy Committee. Dr. Kaufman has also served as a board member and as President in the Northeastern Section of the AUA. Dr. Kaufman has also been a member of the Executive Committee of the New York State Urological Society for many years and has served as its President.

Ronald P. Kaufman, Jr., MDProfessor of UrologyAlbany Medical CollegeAlbany, NY, USA

Thomas E. Keane, MD is Professor and Chairman of the Depart-ment of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.

An avid researcher, Dr. Keane has served as principal investi-gator or co-investigator on more than 20 major clinical and pre-clinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new ther-apies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing com-

pounds. He holds a United States patent for sphingolipid deriva-tives and their use.

Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urol-ogy, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urol-ogy to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.

Thomas E. Keane, MD Professor and Chairman of UrologyMedical University of South Carolina Charleston, SC, USA

Mohit Khera, MD, MBA, MPH is the Professor of Urology and Direc-tor of the Laboratory for Andrology Research at McNair Medical Institute, Baylor College of Medicine. He is also the Medical Direc-tor of the Executive Health Program at Baylor. Dr. Khera received his doctorate from The University of Texas Health Science Center at San Antonio, and completed his residency and internship at

Baylor. He specializes in male infertility, male and female sexual dysfunction, and declining testosterone levels in aging men. Dr. Khera’s research focuses on the efficacy of botulinum toxin type A in treating Peyronie’s disease, as well as genetic and epigenetic studies on post-finasteride syndrome patients and testosterone replacement therapy.

Mohit Khera, MD, MBA, MPHProfessor of UrologyBaylor College of MedicineHouston, TX, USA

Gary M. Kirsh, MD has been the President of The Urology Group, headquartered in Cincinnati, Ohio, since 2009. The group oper-ates integrated surgical, imaging, laboratory, radiation, and clini-cal research services and is the largest provider of urologic care to the Cincinnati/Northern Kentucky/Eastern Indiana metropolitan service region, serving over two million people. Dr. Kirsh earned his medical degree from the University of Chicago, Pritzker School of Medicine in 1984. He completed his urology residency at Case Western Reserve University in Cleveland, Ohio, in 1989.

Dr. Kirsh has a long history of involvement in organized urol-ogy, urologic health policy, and advocacy. He is a past Chairman

of UROPAC (2009-2013), and a past-president of the Ohio Uro-logic Society (1998-1999), the American Association of Clinical Urologists (2007-2008), and the North Central Section of the AUA (2015-2016) . In 2008, Dr. Kirsh was instrumental in found-ing LUGPA. Dr. Kirsh has served as Secretary, President-Elect, and President (2014-2016) of LUGPA. Currently, Dr. Kirsh is LUGPA’s Chairman of Political Affairs.

Dr. Kirsh has frequently spoken to urologists across the coun-try about socioeconomic and political issues facing urology. He has provided legislative testimony in support of physicians’ is-sues at both the state and federal levels.

Gary M. Kirsh, MDPresidentThe Urology GroupCincinnati, OH, USA

Laurence Klotz, MD is the former Chief of Urology at Sunnybrook Health Sciences Centre and former President of the Urological Re-search Society and the Canadian Urological Association. He cur-rently serves as Professor of Surgery at the University of Toronto, holds the Sunnybrook Chair of Prostate Cancer Research, and is the Chairman of the World Uro-Oncology Federation. Dr. Klotz was the Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal, and is now Editor Emeritus of the CUAJ. He was the founder and is chairman of the Canadian Urology Research Consortium (CURC).

Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Ket-tering Cancer Centre in New York in uro-oncology.

Dr. Klotz is a widely published uro-oncologist with over 350

publications and 6 books. His main research interest has been prostate cancer. He is the Associate Editor of the Journal of Urol-ogy, responsible for Prostate Cancer. He serves on the boards of many medical/scientific organizations and journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases, Brazilian Journal of Urology, Italian Journal of Urology, and World Journal of Urology.

Dr. Klotz was awarded the Queen’s Jubilee Medal for meritorious public service in 2012, and the University of Toronto Department of Surgery Lister Prize and the Society of Urologic Oncology Medal in 2013. He received the Harold Warwick Award from the Canadian Cancer Society for ‘outstanding contributions to cancer control’ in 2014. He received the Order of Canada in 2015, and the Richard Wil-liams Award from the AUA in 2016. He received the Dean’s Lifetime Achievement Award from the University of Toronto in 2017.

Laurence Klotz, MDProfessor of SurgeryUniversity of TorontoToronto, ON, Canada

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiolo-gy residency at Pennsylvania Hospital of the University of Penn-sylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology and American Board of

Nuclear Medicine. Dr. Koo is an active member of multiple soci-eties and serves as the Chair of Nuclear Medicine for the RSNA Scientific Program Committee, Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Chair of the Prostate Cancer Working Group at the SNMMI. Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.

Phillip J. Koo, MD Chief of Diagnostic ImagingBanner HealthPhoenix, AZUSA

Francisco G. La Rosa, MD is the Associate Professor in the De-partment of Pathology at the University of Colorado Anschutz Medical Campus and member of the University of Colorado Cancer Center. He is an active clinician, researcher and teacher, board-certified in anatomic and clinical pathology. Additionally, Dr. La Rosa specializes in genitourinary, renal and heart pathol-ogy, as well as an expert in pathology informatics. Dr. La Rosa has more than 90 publications in refereed journals and has sev-eral websites for the teaching of pathology. He is an active mem-ber of many national and international organizations, including

the College of American Pathologists, The American Urological Association, Catholic Medical Association, American Telemedi-cine Association, Asociación Iberoamericana de Teleslud y Tele-medicina, and Peruvian American Medical Association. As an investigator in genitourinary pathology, he is a member and study coordinator for the Southwest Oncology Group (SWOG) Genitourinary Committee, and a collaborator with the research groups led by Dr. E. David Crawford and Thomas Flaig in innova-tive technology for the diagnosis and treatment of prostate and urinary cancer.

Francisco G. La Rosa, MDAssociate ProfessorUniversity of Colorado, DenverAurora, CO, USA

Paul Maroni, MD graduated from the University of Virginia in 1996 and from the University of Illinois College of Medicine in 2000. In 2006, Dr Maroni completed his residency at the Univer-sity of Colorado at Denver and Health Sciences Center prior to receiving fellowship training in Urologic Oncology at Indiana University. He returned to the University of Colorado as a faculty member in 2007. He is the Program Leader of the Urologic Oncol-ogy Program at the University of Colorado.

Dr. Maroni has published on the topics of prostate and testic-ular cancer. His specific clinical and academic interests are mini-mally invasive therapies for prostate cancer, robotic surgery, and surgery for metastatic testicular cancer. He is an investigator for numerous clinical trials about a wide range of subjects, from di-agnostic tools to complementary medicines to immunotherapy for localized prostate cancer.

Paul Maroni, MDProgram Leader of the Urologic Oncology ProgramUniversity of Colorado, Denver Aurora, CO, USA

Arturo Mendoza-Valdés, MD attended medical school at the Na-tional Autonomous University of Mexico (UNAM) in Mexico City. He completed a residency in Urology at the Instituto Nacional de Nutrición “Salvador Zubirán” (INNSZ), also in Mexico City. Dr. Mendoza-Valdés has served as a staff member (1987-2000) and Chief of the Urology Department (1988-1996) at the National Cancer Institute of Mexico. He is currently a Professor in the Urol-ogy Residency Program at INNSZ.

Dr. Mendoza-Valdés is also a former President of the Mexican Urological Association, as well as a former President of the SCS-AUA. In 1998, he and other Mexican urologists founded the Mexi-can Urologic Oncology Association, and he serves as its President and Scientific Committee Chairman to this day.

Dr. Mendoza-Valdés has organized 24 International Sympo-siums of Urologic Oncology in Mexico. He was a member of the scientific committee of the SIU from 1999 to 2013. He is a co-founder of the WUOF (World Urologic Oncology Federation) and has been a member of its steering committee since 2004. He has been a member of the Clinical Practice Guidelines of the AUA (2010-2013), and a member of the Urologic Diagnostic and Ther-apeutic Imaging Committee (2010 to 2016). Dr. Mendoza-Valdés has been a member of the SUO (Society of Urologic Oncology) since 2013. In 2012 he became Honorary Member of the

EAU. He has participated in 3 ICUD panels on prostate cancer and one in penis cancer. He is a member of the editorial board of the CJU. Dr. Mendoza-Valdés has served as faculty at IPCU many times.

Arturo Mendoza-Valdés, MDProfessor of UrologyHospital Médica SurMexico City, Mexico

Mark A. Moyad, MD, MPH occupies an endowed position created and funded entirely by the patients he has helped over the past 15 years. He is the Jenkins/Pokempner Director of Preventive & Complementary Medicine at the University of Michigan Medical Center (Department of Urology) and is also the consulting Direc-tor of Medical Education & Research for the Eisenhower Wellness Institute, a part of the Eisenhower Medical Center. Dr. Moyad re-ceived his MPH degree from the University of South Florida with a focus on epidemiology & dietary supplements, and he received his medical education and degree from the Wayne State Uni-versity School of Medicine. He is the primary author of over 130 published medical journal articles, co-author or author of nine books, and the former editor-in-chief of the medical journal Sem-inars in Preventive & Alternative Medicine.

Dr. Moyad was the former course director or co-director for the annual AUA, ASCO, and SUNA class on Preventive and Al-ternative Medicine. He has also maintained a consulting prac-tice in Complementary and Alternative Medicine for the last 15 years, and he has lectured on breast, prostate, and a variety of other cancers in addition to cardiovascular disease and general health promotion internationally in almost every country and in all 50 states.

Dr. Moyad has and continues to consult for most major mag-azines and television shows devoted to health in the U.S. He cre-ated the Promoting Wellness campaign, which is now utilized by clinicians and patients from Australia to Europe to South Africa.

His current research involves lifestyle changes to reduce can-cer treatment side effects, advocacy, and cancer vaccine testing.

Mark A. Moyad, MD, MPH Director of Preventive & Alternative MedicineUniversity of Michigan Ann Arbor, MI, USA

Dr. Moyad is one of the creators and now the co-chair of the Early Access Program (EAP) committee, whose primary purpose is to negotiate and facilitate the delivery of ground breaking success-

ful phase 3 medications to individuals with the most advanced forms of cancer while these medicines are in the 6-12 month window waiting for FDA approval.

J. Kellogg Parsons, MD, MHS is a board-certified urologist who specializes in diagnosing and treating prostate cancer. He directs clinical trials for the Department of Urology at UC San Diego Health’s Moores Cancer Center.

Dr. Parsons is an expert in nerve-sparing robotic surgery, cryosurgery, and MRI of the prostate, and is internationally rec-ognized for his work in prostate disease. He has repeatedly been named a top doctor in San Diego Magazine’s “Physicians of Ex-ceptional Excellence” annual survey, performed in collaboration with the San Diego County Medical Society. He has also been rec-ognized as one of America’s Best Doctors®.

He has published over 130 scientific research articles, edited four medical textbooks, received multiple research grants, and

serves as an editor on three scientific journals. He has won nu-merous awards for his scientific research, lectures extensively across the US, and in Europe and Asia, and serves on several na-tional committees.

Dr. Parsons completed his residency and fellowship training at John Hopkins School of Medicine in Baltimore. He earned his medical degree from University of Pennsylvania, School of Medi-cine in Philadelphia and holds a Master of Health Science in clini-cal investigation from Johns Hopkins Bloomberg School of Pub-lic Health. He is board certified in urology.

Dr. Parsons is also the award-winning author of the novels Doing Harm and Under the Knife. He is currently at work on his third book.

J. Kellogg Parsons, MD, MHSProfessor of UrologyUC San DiegoLa Jolla, CA, USA

Daniel P. Petrylak, MD is currently Director of Genitourinary On-cology, Professor of Medicine and of Urology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center. He is a recognized international leader in the field. He completed his medical degree at Case Western Reserve University School of medicine, his internal medicine residency at Albert Einstein Col-lege of Medicine/Jacobi Medical center, and fellowship at Memo-rial Sloan Kettering Cancer Center.

Dr. Petrylak is the head of the advanced bladder subcom-mittee in the Southwest Oncology Group (SWOG) Genitourinary Committee. He served principal investigator (PI) or co-PI on seven SWOG clinical trials for genitourinary cancers. Most nota-bly, he served as the PI for a randomized trial that led to the FDA

approval of docetaxel in hormone refractory prostate cancer. He also help to design and served as PI for the SPARC trial, an inter-national registration trial evaluating satraplatin as a second line therapy for hormone refractory prostate cancer.

Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a commit-tee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Can-cer Institute, Cancer Research, and Clinical Cancer Research.

Daniel P. Petrylak, MDProfessor of UrologyYale University New Haven, CT, USA

Wendy Poage, MHA earned her Bachelor of Science degree at the Colorado State University in 1993 and her Masters of Health Care Administration at Webster University in 1997. Wendy has been the President of the Prostate Conditions Education Council since 1998 and the Administrator of Urologic Oncology at the Univer-sity of Colorado Health Sciences Center for over ten years.

Wendy’s vast experience with prostate cancer includes lead-ership positions in renowned educational institutions, hospitals, non-profits and private practice settings. Her unique expertise and areas of interests include bridging the gap between pa-tients, research and their medical providers, cause marketing for challenging demographics and building innovative national and

international programs that are highly sought after by outside entities. Wendy actively participates in research and has a variety of publications, including scientific abstracts and general maga-zine articles. Wendy has also been selected to serve with several affiliated non-profits around the country including her role as Vice President of the National Alliance for State Prostate Cancer Coalitions, Obadiah Cole Foundation and the Prostate Cancer Roundtable. As a highly sought after international consultant and resource, she speaks to both physician and patient groups including recent speaking engagements at the American Uro-logical Association, the American Association of Clinical Chemis-try, and the Future Directions in Urology Symposium.

Wendy L. Poage, MHAPresidentProstate Conditions Education CouncilElizabeth, CO, USA

Robert E. Reiter, MD, MBA , is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Insti-tute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic

surgical management of prostate cancer, as well as the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibod-ies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergradu-ate studies at Yale University and medicine at Stanford University Medical School.

Robert E. Reiter, MD, MBA Professor of UrologyGeffen School of Medicine at UCLALos Angeles, CA, USA

Neal D. Shore, MD is the Medical Director for the Carolina Uro-logic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

Dr. Shore has conducted more than 250 clinical trials, focus-ing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic On-cology Clinical Trials Consortium, and the Large Urology Group Practice Association. He also is a member of the AUA Data Com-mittee, the Bladder Cancer Advocacy Think Tank, and the edi-

torial board of Urology Times. He has numerous articles/peer reviewed publications, and also performs peer review for more multiple journals.

A graduate of Duke University Medical School, Dr. Shore com-pleted a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology train-ing at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Neal D. Shore, MD Director, CPIAtlantic Urology ClinicsMyrtle Beach, SC, USA

Faina Shtern, MD has been leading groundbreaking programs in prostate cancer research, education, awareness and advocacy, with a focus on the advancement of precision diagnostics and their integration with precision treatment as a Founder of AdMe-Tech Foundation since 1997. This work has led to:a. Development, global PI-RADS standardization, clinical eval-

uation, and implementation of precision MRI;b. Establishment of molecular imaging, with priority focus on

PSMA PET;c. Original work in robotics for precision biopsy and treatment;d. Recognition and expansion of radiogenomics; ande. Precedent-setting legislation in US Congress and Massachu-

setts.

Prior to AdMeTech, since 1990, Dr. Shtern served as Chief of the Diagnostic Imaging Research Branch at the National Cancer Institute, and Associate Director for Science and Technology, Of-fice of Women’s Health, Office of the Secretary, US Department of Health and Human Services. She also led radiology research at Harvard Medical School’s Beth Israel Deaconess Medical Center and at Boston Children’s Hospital between 1999 and 2008.

Dr. Shtern has lead and participated in numerous scientific and advisory committees, including the breast cancer study group of the National Academy of Medicine and Vice President Biden’s Cancer Moonshot Program. In 2016, she was named a “Woman of Influence” by the Boston Business Journal.

Faina Shtern, MDPresident and CEOAdMeTech FoundationBoston, MA, USA

Nelson N. Stone, MD is Professor of Urology and Radiation On-cology at The Icahn School of Medicine at Mount Sinai and at the Derald H. Ruttenberg Cancer Center at Mount Sinai. He also serves as CEO of 3D Biopsy, LLC.

Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a general surgical residency in 1981 at the University of Maryland, followed by residency in urol-ogy at the University of Maryland. He then completed a fellow-ship in urologic oncology at Memorial Sloan-Kettering Cancer Center and a research fellowship in biochemical endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elm-hurst Hospital from 1989-1996.

Dr. Stone has founded several medical companies and serves

on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 400 articles, ab-stracts, and book chapters, most on prostate cancer. He invented the real-time technique for prostate seed implantation in 1990 and has trained more than 5,000 physicians worldwide on pros-tate brachytherapy through his company ProSeed. His current company, 3DBiopsy, Inc., is developing variable length biopsy devices, mapping software and an integrated pathology system.

Nelson N. Stone, MDProfessor of Urology and Radiation Oncology Mount SinaiNew York, NY, USA

Priya N. Werahera, PhD is an Associate Professor in the Depart-ments of Pathology and Bioengineering at the University of Colo-rado Anschutz Medical Campus. He received his PhD in Electrical and Computer Engineering in 1994. His main research interests are biomedical imaging, optical spectroscopy, bioinstrumenta-tion, computer modeling, and nanotechnologies for cancer di-agnostics and therapeutics.

Dr. Werahera is a renowned leader in clinical translational research in prostate cancer diagnosis and therapy with over 20 years of experience. He developed a novel computer algorithm and methodology to create equivalent 3D computer models of human prostate specimens. One of his major accomplishments is the proof-of-concept work on template-guided transperineal mapping biopsy protocol to identify low-risk prostate cancer

patients. He led the team of investigators that measured pros-tate tumor growth rates in humans to find out whether there is a difference in growth rates of latent versus aggressive prostate cancer. He proved that maximum tumor doubling times of latent and prostate tumors are not significantly different, as was previ-ously thought.

Dr. Werahera has prototyped a minimally invasive 16g opti-cal biopsy needle capable of diagnosing prostate cancer with very high sensitivity and specificity by inserting an optical sen-sor at the tip of a biopsy needle (US patent). Dr. Werahera is a Co-Founder of Precision Biopsy Inc. Dr. Werahera has 40+ peer reviewed journal and conference publications. He is a Member of the University of Colorado Cancer Center and a Senior Member of the Institution of Electrical and Electronics Engineers (IEEE).

Priya N. Werahera, PhDAssociate Professor of Pathology and BioengineeringUniversity of Colorado, Anschutz Medical Campus.Aurora, CO, USA